By Lina Irawan 
For years, he and classmate David Eng poured their energy into developing this ambitious project. They meticulously built algorithms designed to sift through the intricate patterns of medical imaging, searching for subtle indicators of cardiovascular risk that might escape the human eye, or simply be overlooked in the sheer volume of cases a radiologist handles daily. Their technology showed promise, demonstrating impressive accuracy in laboratory settings. Yet, even as their AI models achieved impressive results, they encountered a formidable barrier: the deeply entrenched, often conservative, healthcare system. Hospitals, burdened by legacy systems, stringent regulations, and a natural skepticism toward unproven technologies, more or less shooed them away. The prevailing sentiment was one of caution, and the path to real-world deployment seemed impassable, leaving Khandwala and Eng contemplating whether it was time to pivot or move on.
The turning point arrived in 2020, a stark and deeply personal validation of their initial premise, when Khandwala’s father suffered a heart attack. The incident, while devastating, brought a chilling revelation. "The cardiologist told us: ‘There was actually a scan in the past that showed he had an increased risk of heart disease, I think we could have caught this earlier,’" Khandwala recounted, now the CEO of Bunkerhill Health. This admission, delivered with a mix of regret and professional candor, illuminated the tragic gap between available data and actionable insight—a gap that their AI was explicitly designed to bridge. "Can you imagine? Think about the millions of patients for whom you could prevent those kinds of heart attacks," he reflected, the personal tragedy solidifying his professional resolve. "The key thing though was: We weren’t unique in having a great idea. Great ideas are everywhere, we just don’t translate them into reality." This experience underscored the critical need for a mechanism to not just identify risks, but to integrate that identification seamlessly into clinical workflows, ensuring that critical information is never missed again.
It was this profound realization that ignited the formal establishment of Bunkerhill Health. Khandwala cofounded the company with Eng in 2019, predating his father’s heart attack but gaining immense renewed purpose from it. The company takes its intriguing name from "Bunker Hill," a single-season 2010s CBS TV show that, despite being decisively panned by critics, harbored a central, sticky idea: that medicine can iterate faster. This ethos became the startup’s guiding principle. In an industry often characterized by slow adoption cycles, bureaucratic inertia, and a resistance to change, Bunkerhill positioned itself as an accelerant, a catalyst for rapid improvement. The startup, then, deploys sophisticated AI agents to handle the tasks that hospitals most urgently need to solve, extending far beyond the initial vision of radiology scan analysis. These agents tackle challenges ranging from alleviating notoriously long patient wait times, reducing the incidence of missed follow-up appointments, to clearing overwhelming paperwork backlogs. Crucially, Bunkerhill doesn’t dictate use cases; rather, it operates responsively, with hospitals approaching the company to inquire if its versatile AI agents can solve specific, pressing operational or clinical problems. This client-driven approach ensures that their solutions are directly addressing real pain points within the healthcare ecosystem.
Currently, Bunkerhill Health’s "Carebricks" platform is making significant inroads, working with 15 prominent health systems across the United States. This impressive roster includes some of the nation’s most respected institutions, such as Cleveland Clinic, Mayo Clinic, Ballad Health, Intermountain Health, Sentara Health, Endeavor Health, and The University of Texas Medical Branch (UTMB) Health. The "Carebricks" platform itself is a testament to Bunkerhill’s comprehensive approach, embedding both operational AI agents—designed to streamline administrative tasks and improve efficiency—and nine distinct clinical FDA-cleared AI algorithms. The FDA clearance is a critical differentiator in the highly regulated medical field, signifying rigorous validation, safety, and efficacy, building trust among clinicians and patients alike. These advanced algorithms include one specifically engineered to detect silent heart valve disease early, a condition often missed in routine examinations but carrying significant risk of stroke or heart failure if left undiagnosed. Another algorithm assesses osteoporosis risk, enabling earlier intervention to prevent debilitating fractures in at-risk populations. This blend of administrative and clinical intelligence allows Bunkerhill to address a wide spectrum of hospital needs, positioning itself as a holistic AI partner.
The company’s rapid growth and proven impact recently culminated in a significant financial milestone, disclosed for the first time exclusively to Fortune. Bunkerhill Health successfully closed its $25 million Series B funding round, spearheaded by Khosla Ventures, a titan in the venture capital world known for its prescient investments in groundbreaking technology. This latest infusion of capital brings Bunkerhill’s total funding to an impressive $55 million, underscoring strong investor confidence in its mission and technology. Esteemed venture capital firms such as Sequoia, Felicis, Optum Ventures (which specializes in healthcare innovation), and Y Combinator, a renowned startup accelerator, also participated in this pivotal round. The involvement of Vinod Khosla, a legendary figure celebrated for his early backing of OpenAI and his co-founding of Sun Microsystems, speaks volumes about the perceived potential of Bunkerhill. Khosla, who has been strategically backing healthcare companies for decades, articulated a clear shift in the industry’s receptiveness to technology. He stated unequivocally that AI is no longer an option but "a mandate" for healthcare institutions.
Khosla elaborated on this paradigm shift in an interview with Fortune, contrasting the current climate with past attitudes. "Software used to be a pain for hospitals," he explained. "There wasn’t a push to adopt it, other than the medical record, and it sort of got in the way. Now, every hospital system is trying to adopt AI. When you switch the words ‘AI’ from ‘software,’ everyone wants to and needs to talk about it." This observation highlights the psychological and practical evolution in how healthcare leaders view technological integration. AI, with its promise of intelligent automation, predictive analytics, and enhanced decision-making, is seen as a fundamentally different beast from traditional software, offering solutions to systemic problems that have long plagued the industry.
This sentiment is strongly echoed by Bunkerhill’s clients, particularly at UTMB Health, where a substantial 22 of Bunkerhill’s AI agents are currently deployed, tackling a variety of operational and clinical challenges. Dr. Peter McCaffrey, UTMB’s chief AI officer, articulated the legitimate need for AI in healthcare, even amidst broader market speculation about an "AI bubble." While emphasizing that the sacred doctor-patient relationship must remain "sacrosanct," McCaffrey firmly believes AI is uniquely positioned to augment human capabilities. "We may be in an AI bubble overall, but if there’s one place where the need for AI is extremely legitimate, I’d say it’s healthcare," said McCaffrey. His insightful perspective further clarified the practical application of AI: "We don’t need superintelligence to solve our biggest problems. We need average intelligence." This means AI that can perform routine, data-intensive tasks with consistent accuracy and speed, freeing up highly skilled medical professionals to focus on complex decision-making and direct patient care. Examples of such "average intelligence" applications might include automating patient intake, optimizing scheduling to reduce no-shows, flagging potential drug interactions, or even assisting with discharge planning to prevent readmissions.
The surge of investment into healthcare AI administrative startups has indeed become noticeable, prompting some industry observers, including Fortune writer Allie Garfinkle, to express a minor hesitation about the sheer volume of new entrants. Garfinkle brought her query—"are there too many AI healthcare admin startups?"—to Alfred Lin, a distinguished partner at Sequoia, who has been a staunch supporter of Bunkerhill since leading its $6.5 million seed round in 2023. Lin’s response was characteristically bullish on the power of market dynamics. "If your premise is that there are too many, I think it’s great that there’s too many," said Lin. "Then, there’s innovation and competition and hopefully the best ones win. If it’s too few, that would be a bad thing. I much prefer having 1,000 flowers bloom, and the best ones will become durable over time." This perspective underscores the venture capital ethos of fostering a vibrant ecosystem where multiple solutions can emerge, allowing the most effective and resilient to ultimately prevail.
Lin, renowned as Sequoia’s lead backer of transformative companies like DoorDash, Airbnb, Citadel Securities, and Reddit, further elaborated on his investment philosophy. He is particularly drawn to industries characterized by what he terms "regulatory capture," where established regulations and incumbents create high barriers to entry, yet also harbor immense potential for disruption. "Like real estate with Airbnb, or Uber and DoorDash, there’s a regulatory capture in those industries, and healthcare isn’t any different," Lin explained. He sees healthcare’s complex regulatory environment not just as an obstacle, but as a fertile ground for innovation for companies like Bunkerhill that can successfully navigate it. "What [Bunkerhill] is trying to do across parties is hard, but it’s also undeniable that there’s opportunity to improve health outcomes." This recognition of the dual nature of regulatory hurdles—as both challenge and opportunity—is a hallmark of successful venture investing in complex sectors.
Nishith Khandwala has his own incisive take on the question of market saturation in healthcare AI. His perspective cuts directly to Bunkerhill’s core value proposition and its strategic differentiation. "Why should a hospital need to work with 100 different companies to solve 100 different problems?" Khandwala challenged. "Most companies are still solving one narrow problem, and we’ve moved past that." This statement encapsulates Bunkerhill’s ambition to be a comprehensive, integrated AI partner for health systems, offering a unified platform—Carebricks—that can deploy multiple AI agents and algorithms to address a broad spectrum of clinical and operational needs. Instead of a patchwork of disparate point solutions, each requiring its own integration, maintenance, and training, Bunkerhill offers a cohesive ecosystem that aims to simplify, streamline, and scale AI adoption. This integrated approach not only reduces complexity for hospitals but also maximizes the potential for synergistic improvements across various functions, ultimately accelerating the pace at which medical iteration can occur, just as the obscure TV show that inspired its name once envisioned. As healthcare continues its inevitable digital transformation, Bunkerhill Health stands poised to play a pivotal role, leveraging AI to not only prevent future tragedies like Khandwala’s father’s heart attack but to fundamentally reshape the efficiency and efficacy of medical care for millions.
